​
A DAY WITH THE JUDGES
Program Agenda​
October 27 - 28, 2023
​
(JUDGES ATTEND FREE)
*DOCTORS and PAs: Approved for 16 hours of AMA PRA Category 1 Credits™
*JUDGES: Approved for 7 Judicial Credit Hours for Judges.
"LAWYERS: Approved by Oklahoma MCLE for Maximum 11.50 Credits (General 7.50 and Ethics 4.0)
*NURSES: Approved for 6 hours of Nursing Credits for the Supplemental Pre-course
*Oklahoma Medical Board: Approved by the for one (1) hour of education in pain management or *one (1) hour of education in opioid use or addiction each year preceding an application for renewal of a license.
​
A DAY WITH THE JUDGES
Reference Documents and Resources
MARIJUANA (CANNABIS): THC AND CBD
FEDERAL AND STATE STATUTES, MEDICAL, ETHICAL AND LIABILITY ISSUES:
​
​
Marijuana, Legal Aspects
Cannabis (Marijuana,) Medical Aspects
SAMHSA References and Relevant Resources
-
Technology Transfer Centers (TTC) Program marijuana resources
-
Drug Facts: Marijuana | United States Drug Enforcement Administration
-
Early-Onset, Regular Cannabis Use Is Linked to IQ Decline | NIDA
-
Marijuana and Public Health | Centers for Disease Control and Prevention
-
Marijuana: Is there a Link Between Marijuana Use and Psychiatric Disorders? | NIDA
"Ethics and Medical Marijuana:
What you need to know”
Patricia Carothers, BSN, RN, MS, CCM
From Health2 Resources on Vimeo. The video is available for your viewing pleasure
Click Here:
​
Medical Cannabis Pharmacogenomics
and Drug-Drug Interactions
​
Abstract: The therapeutic applications of medical cannabis and cannabinoid drugs is controversial, however the number of medical conditions in which cannabinoids and cannabis have shown promise as therapeutic treatments is expanding.
The occurrence of side effects from cannabinoids is still a concern, especially with the wide variability in drug levels and response that has been observed. This is compounded by possible interactions with prescription drugs. Application of pharmacogenomics (PGx) and knowledge of drug-drug interactions could help patients and doctors navigate the complexities of combining prescription drugs and cannabis compounds.
Genetic variants in several drug metabolizing enzymes may impact response to cannabinoids, including CYP3A4, CYP2C9, and CYP2C19. Furthermore, drug interactions caused by cannabinoids may also be mediated by drug metabolizing enzymes (e.g. CYP2C9, CYP2D6, CYP2B6, CYP1A1) and possibly drug transporters such as ABCB1.
Understanding how commonly prescribed drugs and cannabinoids interact could help reduce risks associated with polydrug regimens. This presentation will discuss PGx testing for cannabis and potential impacts on commonly prescribed pharmaceuticals.
BRIEF historical note
In early American history, the term “marijuana” was non-existent and “cannabis” was the primary term used to classify the plant.
Between 1910 and 1920, nearly a million Mexicans migrated into the United States seeking refuge from the Mexican Revolution.
During this time, anti-Mexican sentiment had begun to steep and the term “marijuana” arose as a negative correlation of its use by Mexican immigrants.
Soon after, rumors began to surface, warning Americans of the dangerous and homicidal tendencies caused by using “Mexican cannabis” or “locoweed,”which lead to an even greater rise in anti-Mexican sentiment.
As the negative perception of cannabis intensified, the government began regulating cannabis more aggressively.
By 1927, 11 states had passed anti-marijuana laws and by the 1930's anti-marijuana propaganda and the fear of “Reefer Madness” was in full swing.
After the passing of the Marihuana Tax Act of 1937, which imposed heavy, unrealistic taxes on the possession, sale, and transportation of the plant, the federal government had effectively banned “marijuana,” paving the way for decades of cannabis prohibition.